DURATION OF IMMUNE RESPONSE INDUCED BY THE VACCINE BASED ON RECOMBINANT Ag85, TB10 AND FliC PROTEINS

Already about one hundred years BCG remains the only widely used tuberculosis (TB) vaccine. It is known that intensity of the BCG-induced Th1 immune response decreases over time and comes to naught within 10-15 years. It significantly distinguishes BCG from the vaccines providing a lifelong protection such as vaccines against poliomyelitis or measles, and can be bound to natural restriction of duration of a persistence of the BCG-induced CD4+ T-cells. Data on insufficient ability of BCG to stimulate life-long immunological memory is accumulating. Earlier in our lab on the model of rather resistant to TB C57BL/6 mice infection with the virulent laboratory strain of Mycobacterium tuberculosis (Mtb) H37Rv protective activity (comparable to that of BCG Russia) of 3 subunit vaccine variants was demonstrated as assessed by lung and spleen CFU counts and life span of animals after infection. The aim of this study was to study the characteristics and duration of the immune response induced by the most effective variant of these vaccines. Groups of C57BL/6 mice were vaccinated intramuscularly twice with two-week intervals with 10 μg protein conjugated to 200 μl of an aluminum hydroxide emulsion. Immune response (production of specific antibodies, vaccine proteinstimulated production of interferon gamma and proliferation in vitro) was monitored during 10 months after vaccination. We have shown that the test vaccine induces in mice the formation of long-term immunological memory to a bacterial antigen. Moreover, in the presence of glutoxim the immunological memory spectrum shifts to a "protective" type, i.e. the predominance of the cellular component of the immune response over the antibody response is stimulated. The next step will be the investigation of vaccine effectiveness for revaccination after primary BCG immunization. 

1. Еремеев В.В., Гергерт В.Я. Изучение способности препарата глутоксим влиять на антимикобактериальную активность фагоцитов чувствительных и устойчивых к туберкулёзу мышей // Туберкулез и болезни легких, 2013. № 7. С. 43-47. [Yeremeev V.V., Gergert V.Ya. Ivestigation of the ability of glutoxim to affect the antimycobacterial activity of phagocytes in tuberculosis susceptible and resistant mice. Tuberkulez i bolezni legkikh = Tuberculosis and Lung Desiases, 2013, no. 7, pp. 43-47. (In Russ.)]

2. Еремеев В.В., Духовлинов И.В., Орлов А.И., Маленко А.Ф., Федорова Е.А., Балазовский М.Б., Гергерт В.Я. Исследование протективных свойств вакцинного препарата на основе рекомбинантных белков Ag85, TB10 И FliC // Медицинская иммунология, 2017. Т. 19, № 2. С.197-202. [Yeremeev V.V., Dukhovlinov I.V., Orlov A.I., Malenko A.F., Fedorova E.A., Balazovsky M.B., Gergert V.Ya. Studies on protective effects of a vaccine, based on recombinant Ag85, TB10 and FliC proteins. Meditsinskaya immunologiya = Medical Immunology (Russia), 2017, Vol. 19, no. 2, pp. 197-202. (In Russ.)] doi: 10.15789/1563-0625-2017-2-197-202.

3. A Randomized, Placebo Controlled, Partially Blinded Phase II Study to Evaluate Safety, Immunogenicity, and Prevention of Infection With Mycobacterium tuberculosis of AERAS-404 and BCG Revaccination in Healthy Adolescents (040-404). Available from: http://clinicaltrials.gov/show/NCT02075203.

4. Connor L.M., Harvie M.C., Rich F.J., Quinn K.M., Brinkmann V., Le Gros G., Kirman J.R. A key role for lung-resident memory lymphocytes in protective immune responses after BCG vaccination. Eur. J. Immunol., 2010, Vol. 40, no. 9, pp. 2482-2492.

5. Coppola M., Arroyo L., van Meijgaarden K.E., Franken K.L., Geluk A., Barrera L.F., Ottenhoff T.H.M. Differences in IgG responses against infection phase related Mycobacterium tuberculosis (Mtb) specific antigens in individuals exposed or not to Mtb correlate with control of TB infection and progression. Tuberculosis, 2017, Vol. 106. pp. 25-32.

6. Fournillier A., Frelin L., Jacquier E., Ahlén G., Brass A., Gerossier E., Holmström F., Broderick K.E., Sardesai N.Y., Bonnefoy J.Y., Inchauspé G., Sällberg M. Heterologous prime/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus. J. Infect. Dis., 2013, Vol. 208, no. 6, pp. 1008-1019.

7. Kaufmann S.H., Weiner J., von Reyn C.F. Novel approaches to tuberculosis vaccine development. Int. J. Infect. Dis., 2017, Vol. 56, pp. 263-267.

8. Leroux-Roels I., Forgus S., De Boever F., Clement F., Demoitié M.A., Mettens P., Moris P., Ledent E., LerouxRoels G., Ofori-Anyinam O.l. Improved CD4+ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: A randomized trial. Vaccine, 2013, Vol. 31, no. 17, pp. 2196-2206.

9. Lindenstrom T., Agger E.M., Korsholm K.S., Darrah P.A., Aagaard C., Seder R.A., Rosenkrands I., Andersen P. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J. Immunol., 2009, Vol. 182, no. 12, pp. 8047-8055.

10. Lindenstrom T., Knudsen N.P., Agger E.M., Andersen P. Control of chronic Mycobacterium tuberculosis infection by CD4 KLRG1- IL-2-secreting central memory cells. J. Immunol., 2013, Vol. 190, no. 12, pp. 6311-6319.

11. Lu S. Heterologous prime-boost vaccination. Curr. Opin. Immunol., 2009, Vol. 21, no. 3, pp. 346-351.

12. Orme I.M. The Achilles heel of BCG. Tuberculosis (Edinb.), 2010, Vol. 90, no. 6, pp. 329-332.

13. Reither K., Katsoulis L., Beattie T., Gardiner N., Lenz N., Said K., Mfinanga E., Pohl C., Fielding K.L., Jeffery H., Kagina B.M., Hughes E.J., Scriba T.J., Hanekom W.A., Hoff S.T., Bang P., Kromann I., Daubenberger C., Andersen P., Churchyard G.J. Safety and immunogenicity of H1/IC31(R), an adjuvanted TB subunit vaccine, in HIVinfected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial. PLoS ONE, 2014, Vol. 9, no. 12, e114602. doi: 10.1371/journal.pone.0114602.

14. Soares A.P., Kwong Chung C.K., Choice T., Hughes E.J., Jacobs G., van Rensburg E.J., Khomba G., de Kock M., Lerumo L., Makhethe L., Maneli M.H., Pienaar B., Smit E., Tena-Coki N.G., van Wyk L., Boom W.H., Kaplan G., Scriba T.J., Hanekom W.A. Longitudinal changes in CD4(+) T-cell memory responses induced by BCG vaccination of newborns. J. Infect. Dis., 2013, Vol. 207, no. 7, pp. 1084-1094.

15. Tyagi A.K., Nangpal P., Satchidanandam V. Development of vaccines against tuberculosis. Tuberculosis (Edinb), 2011, Vol. 91, no. 5, pp. 469-478.

16. Wells S.M., Kantor A.B., Stall A.M. CD43(S7) expression identifies peripheral B-cell subsets. J. Immunol., 1994, Vol. 153, no. 12, pp. 5503-5515.